Willrich, Maria Alice Vieira; Hirata, Mario Hiroyuki 
; Bernik, Marcia Martins Silveira; Dorea, Egidio Lima; Bertolami, Marcelo Chiara; Faludi, André Arpad; Hirata, Rosario Dominguez Crespo
Source: Clinical Chemistry. Conference titles: AACC Annual Meeting. Unidades: FCF, HU
Subjects: POLIMORFISMO, EXPRESSÃO GÊNICA, FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WILLRICH, Maria Alice Vieira et al. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 05 dez. 2025. , 2007APA
Willrich, M. A. V., Hirata, M. H., Bernik, M. M. S., Dorea, E. L., Bertolami, M. C., Faludi, A. A., & Hirata, R. D. C. (2007). CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Willrich MAV, Hirata MH, Bernik MMS, Dorea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. 2007 ; 53( 6): A151.[citado 2025 dez. 05 ]Vancouver
Willrich MAV, Hirata MH, Bernik MMS, Dorea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin. Clinical Chemistry. 2007 ; 53( 6): A151.[citado 2025 dez. 05 ]
